Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CDC25A | P30304 | 1/20 | 0.31 |
| ▸ | CDC25C | P30307 | 1/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096007 | 0.81 | MAPK14 (0.56) | TSHRKDM4EALDH1A1MAPK13MAPK12 | |
| SCHEMBL6095998 | 0.81 | MAPK14 (0.56) | TSHRKDM4EALDH1A1MAPK13MAPK12 | |
| SCHEMBL6097195 | 0.67 | MAPK14 (0.61) | SMN1; SMN2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6097197 | 0.67 | MAPK14 (0.61) | SMN1; SMN2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7052740 | 0.66 | KDM4E (0.46) | TSHRKDM4EALDH1A1SMN1; SMN2MAPK13 | |
| SCHEMBL12671106 | 0.59 | TSHR (0.65) | TSHRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3223085 | 0.59 | TSHR (0.69) | TSHRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2459851 | 0.58 | ALDH1A1 (0.47) | TSHRKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL19898834 | 0.58 | ALDH1A1 (0.52) | TSHRCDC25BKDM4EALDH1A1HPGD | |
| SCHEMBL6502508 | 0.57 | KDM4E (0.51) | KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | IL1B, IL1A, TNF | TSHR 3976/4885CDC25B 1123/4885KDM4E 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.